Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Appoints Robert Spiegel, M.D., FACP, to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the...
July 08, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Patent Issued for Menadione for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash

SOUTH SAN FRANCISCO, Calif., July 8, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
June 07, 2010 10:09 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Announces Financing of Up to $100 Million

SOUTH SAN FRANCISCO, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
June 07, 2010 07:00 ET | Source: Talon Therapeutics, Inc.

Data From Pivotal Phase 2 RALLY Trial Show Marqibo Produced Compelling Single-Agent Anti-Leukemic Efficacy in Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia

Marqibo administered as third-, fourth-, fifth-, and sixth-line single-agent therapy 35% overall response rate with a predictable and manageable toxicity profile 20% complete response...
June 03, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
May 14, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Reports First Quarter 2010 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported...
April 27, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Completes Pre-NDA Meeting With FDA for Marqibo in Adult Acute Lymphoblastic Leukemia

SOUTH SAN FRANCISCO, Calif., April 27, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
April 22, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences to Present Complete Data From Pivotal Phase 2 Trial of Marqibo in Acute Lymphoblastic Leukemia at American Society of Clinical Oncology 2010 Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 22, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
March 30, 2010 08:30 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Receives Notice of Allowance for Menadione Patent for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash

SOUTH SAN FRANCISCO, Calif., March 30, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
March 25, 2010 16:45 ET | Source: Talon Therapeutics, Inc.

Hana Biosciences Reports Fourth Quarter and Year End 2009 Financial Results

SOUTH SAN FRANCISCO, Calif., March 25, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported...